<DOC>
	<DOCNO>NCT02779569</DOCNO>
	<brief_summary>To evaluate safety clinical efficacy ultra-low-dose decitabine Chinese MDS</brief_summary>
	<brief_title>A Clinical Trial Evaluating Efficacy Ultra Low Dose Decitabine Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description>To develop highly effective safe protocol , multi-center , prospective clinical trial conduct China , aim evaluate grade III IV hematologic toxicity clinical efficacy subcutaneous injection ultra-low-dose decitabine ( 5 7 mg/m2 ) treatment myelodysplastic syndrome ( MDS ) , decitabine dose 20 mg/m2 control .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Men woman age 18 80 year ; 2 . Patients high risk MDS assess International Prostate Symptom Score ( IPSS ) ; 3 . Chronic myelomonocytic leukemia ( CMML ) patient abnormal white blood cell count , extremely low platelet count organ infiltration ( hepatomegaly , splenomegaly ) require therapy ; 4 . Patients low risk MDS identify IPSS score secondary MDS , platelet count &lt; 20*10^9/L , response erythropoietin ( EPO ) ( non5q deletion syndrome ) presence disease symptom blood transfusion dependence , response EPO/lenalidomide ( 5q deletion syndrome ) presence disease symptom blood transfusion dependence ; 5 . Patients Eastern Cooperative Oncology Group ( ECOG ) 0 2 ; 6 . Patients expect lifespan 6 month ; 7 . Patients aspartate aminotransferase ( AST ) &lt; 2.5 time higher normal upper limit , alanine aminotransferase ( ALT ) &lt; 2.5 time higher normal upper limit , total bilirubin &lt; 1.5 time higher normal upper limit , serum creatinine &lt; 1.5 time higher normal upper limit ; 8 . Subjects recovery toxicity , undergo therapy 4 week prior first trial , receive nitrosourea therapy bone marrow transplantation 6 week prior first trial ; 9 . Female subject menopausal , underwent surgical sterilization , effective contraception ( oral contraceptive , injectable contraceptive , intrauterine device , contraceptive patch , male sterilization ) prior enrollment trial , negative serum urine pregnancy test screening ; 10 . No insemination give male subject treatment within 2 month posttreatment ; 11 . Subjects comply study protocol ; 12 . Subjects sign informed consent , indicate understood purpose , procedure potential benefit trial willing participate trial . 1 . Patients diagnose acute myeloid leukemia ( primitive bone marrow cell proportion 20 % high ) progressive malignant disease ; 2 . Patients receive treatment drug within 30 day prior first administration decitabine ; 3 . Patients receive radiotherapy within 14 day prior first administration decitabine ; 4 . Patients uncontrolled heart disease congestive heart failure ; 5 . Patients uncontrolled restrictive obstructive pulmonary disease ; 6 . Patients active viral , bacterial invasive fungal infection ; 7 . Patients complicate autoimmune hemolytic anemia immune thrombocytopenia ; 8 . Patients history use azacitidine decitabine ; 9 . Patients seropositive HIV ; 10 . Patients mental disorder completely cooperate treatment follow ; 11 . Patients bone marrow sample ; 12 . Subjects allergic decitabine vehicle ; 13 . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>